Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2374)
All Articles published online
|
Oct 21, 2007 (publication date) through Jan 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i39/5238.htm |
| Number | Citing Articles |
| 1 |
Abullah Alfawaz, Sultan Alrashidi, Hatem Kalantan, Hani Al-Mezaine, Ahmed M. Abu El-Asrar. Cataract surgery under systemic infliximab therapy in patients with refractory uveitis associated with Behcet disease. Annals of Saudi Medicine 2014; 34(4): 328 doi: 10.5144/0256-4947.2014.328
|
| 2 |
Anita Annaházi, Tamás Molnár. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/832395
|
| 3 |
Walter Reinisch, William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Marion Blank, Yinghua Lang, Jewel Johanns, Jean Frédéric Colombel, Daniel Present, Bruce E. Sands. Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies. Inflammatory Bowel Diseases 2012; 18(2): 201 doi: 10.1002/ibd.21697
|
| 4 |
Nuray Uslu, Yusuf Usta, Inci Nur Saltik-Temizel, Hulya Demir, Figen Gürakan, Hasan Ozen, Aysel Yüce. Ineffectiveness of infliximab therapy in severe infantile Crohn's disease. Journal of Crohn's and Colitis 2010; 4(1): 106 doi: 10.1016/j.crohns.2009.08.004
|
| 5 |
Tatsushi Kawaguchi, Yuko Kawazoe, Koju Kamoi, Masaru Miyanaga, Hiroshi Takase, Sunao Sugita, Manabu Mochizuki. Clinical course of patients with Behçet’s uveitis following discontinuation of infliximab therapy. Japanese Journal of Ophthalmology 2014; 58(1): 75 doi: 10.1007/s10384-013-0283-3
|
| 6 |
Daniel J Wong, Eve M Roth, Joseph D Feuerstein, Vitaliy Y Poylin. Surgery in the age of biologics. Gastroenterology Report 2019; 7(2): 77 doi: 10.1093/gastro/goz004
|
| 7 |
W. Miehsler, G. Novacek, H. Wenzl, H. Vogelsang, P. Knoflach, A. Kaser, C. Dejaco, W. Petritsch, M. Kapitan, H. Maier, W. Graninger, H. Tilg, W. Reinisch. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. Journal of Crohn's and Colitis 2010; 4(3): 221 doi: 10.1016/j.crohns.2009.12.001
|
| 8 |
Melany Worbes-Cerezo, Beenish Nafees, Andrew Lloyd, Katy Gallop, Imran Ladha, Cicely Kerr. Disutility Study for Adult Patients with Moderate to Severe Crohn’s Disease. Journal of Health Economics and Outcomes Research 2023; : 47 doi: 10.36469/jheor.2019.9685
|
| 9 |
Xiaoling Li, Mudan Zhang, Gaoshi Zhou, Zhuo Xie, Ying Wang, Jing Han, Li Li, Qirui Wu, Shenghong Zhang. Role of Rho GTPases in inflammatory bowel disease. Cell Death Discovery 2023; 9(1) doi: 10.1038/s41420-023-01329-w
|
| 10 |
Melany Worbes-Cerezo, Beenish Nafees, Andrew Lloyd, Katy Gallop, Imran Ladha, Cicely Kerr. Disutility Study for Adult Patients with Moderate to Severe Crohn’s Disease. Journal of Health Economics and Outcomes Research 2019; 6(2): 47 doi: 10.36469/9685
|
| 11 |
Sultan Al Rashidi, Abdullah Al Fawaz, Dustan Kangave, Ahmed M. Abu El-Asrar. Long-term Clinical Outcomes in Patients with Refractory Uveitis Associated with Behçet Disease Treated with Infliximab. Ocular Immunology and Inflammation 2013; 21(6): 468 doi: 10.3109/09273948.2013.779727
|
| 12 |
Michael B. Sprakes, Alexander C. Ford, Lisa Warren, Dan Greer, John Hamlin. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience. Journal of Crohn's and Colitis 2012; 6(2): 143 doi: 10.1016/j.crohns.2011.07.011
|
| 13 |
Manfred Zierhut, Ahmet M. Abu El-Asrar, Bahram Bodaghi, Ilknur Tugal-Tutkun. Therapy of Ocular Behçet Disease. Ocular Immunology and Inflammation 2014; 22(1): 64 doi: 10.3109/09273948.2013.866257
|
| 14 |
Cong Dai, Yi-Nuo Wang, Wen-Ning Tian, Yu-Hong Huang, Min Jiang. Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis. Revista Española de Enfermedades Digestivas 2023; doi: 10.17235/reed.2023.9537/2023
|
| 15 |
Thomas R. Einarson, Basil G. Bereza, Xin Ying Lee, Filippo Lelli. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Current Medical Research and Opinion 2017; 33(8): 1433 doi: 10.1080/03007995.2017.1335001
|
| 16 |
Gregorio J. Martínez-Romero, Ana Alvariño, Esther Hinojosa, Maria Mora, Lorena Oltra, Nuria Maroto, Isabel Ferrer, María Dolores Hinojosa, Joaquin Ernesto Hinojosa. Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease. Revista Española de Enfermedades Digestivas 2019; 111 doi: 10.17235/reed.2019.5600/2018
|
| 17 |
Annemay M. H. Stoker, Leslie Logghe, Mirjam C. M. van der Ende-van Loon, Erik J. Schoon, Ramon-Michel Schreuder, Arnold Stronkhorst, Lennard P. L. Gilissen. Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission. Clinical and Experimental Medicine 2023; 23(6): 2789 doi: 10.1007/s10238-023-00994-6
|
| 18 |
Laura Guberna, Olga P. Nyssen, María Chaparro, Javier P. Gisbert. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. Journal of Clinical Medicine 2021; 10(10): 2132 doi: 10.3390/jcm10102132
|
| 19 |
Veerle JAA Nuij, Colin J de Haar, C Janneke van der Woude. Trial discontinuation: lessons for future trial design?. Clinical Investigation 2012; 2(2): 147 doi: 10.4155/cli.11.185
|
| 20 |
Andreas Stallmach, Stefan Hagel, Tony Bruns. Adverse effects of biologics used for treating IBD. Best Practice & Research Clinical Gastroenterology 2010; 24(2): 167 doi: 10.1016/j.bpg.2010.01.002
|
| 21 |
Hang Hock Shim, Cynthia H. Seow. Treatment of Inflammatory Bowel Disease with Biologics. 2018; : 141 doi: 10.1007/978-3-319-60276-9_10
|
| 22 |
Vito Annese, Rahul Nathwani, Maryam Alkhatry, Ahmad Al-Rifai, Sameer Al Awadhi, Filippos Georgopoulos, Ahmad N. Jazzar, Ahmed M. Khassouan, Zaher Koutoubi, Mazen S. Taha, Jimmy K. Limdi. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therapeutic Advances in Gastroenterology 2021; 14 doi: 10.1177/17562848211065329
|
| 23 |
Marina Salido Olivares, Estíbaliz Loza Santamaría. Efficacy and safety of the optimisation of biological therapy in non-infectious uveitis: Systematic review. Seminars in Arthritis and Rheumatism 2022; 52: 151944 doi: 10.1016/j.semarthrit.2021.11.010
|
| 24 |
Renato Caviglia, Ivo Boškoski, Michele Cicala. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008; 7(5): 617 doi: 10.1517/14740338.7.5.617
|
| 25 |
J. P. Gisbert, A. C. Marín, M. Chaparro. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐TNF therapy. Alimentary Pharmacology & Therapeutics 2015; 42(4): 391 doi: 10.1111/apt.13276
|
| 26 |
Javier P Gisbert, Alicia C Marín, María Chaparro. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2016; 111(5): 632 doi: 10.1038/ajg.2016.54
|
| 27 |
Alfredo Adán, Victoria Hernandez, Santiago Ortiz, Juan Jose Molina, Laura Pelegrin, Gerard Espinosa, Raimon Sanmartí. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions. International Ophthalmology 2010; 30(5): 577 doi: 10.1007/s10792-010-9372-1
|
| 28 |
Yu Nishida, Shuhei Hosomi, Kenji Watanabe, Kimihiko Watanabe, Tomomi Yukawa, Koji Otani, Yasuaki Nagami, Fumio Tanaka, Koichi Taira, Noriko Kamata, Hirokazu Yamagami, Tetsuya Tanigawa, Toshio Watanabe, Yasuhiro Fujiwara. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scandinavian Journal of Gastroenterology 2018; 53(5): 579 doi: 10.1080/00365521.2017.1403647
|
| 29 |
Joana Torres, Ray K. Boyapati, Nicholas A. Kennedy, Edouard Louis, Jean-Frédéric Colombel, Jack Satsangi. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology 2015; 149(7): 1716 doi: 10.1053/j.gastro.2015.08.055
|
| 30 |
Cátia Rocha, Paula Lago, Samuel Fernandes, Luís Correia, Francisco Portela, Ana Isabel Vieira, Marta Patita, Bruno Arroja, Paula Ministro, Catarina Alves, Cláudia Camila Dias, Fernando Magro. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. Therapeutic Advances in Gastroenterology 2020; 13 doi: 10.1177/1756284820965790
|
| 31 |
David R. Minor, Kevin Chin, Mohammed Kashani-Sabet. Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis. Cancer Biotherapy and Radiopharmaceuticals 2009; 24(3): 321 doi: 10.1089/cbr.2008.0607
|
| 32 |
Maria H. Lönnkvist, Ragnar Befrits, Jon O. Lundberg, Joachim Lundahl, Ulrika L. Fagerberg, Henrik Hjortswang, Marianne van Hage, Per M. Hellström. Infliximab in clinical routine: experience with Crohnʼs disease and biomarkers of inflammation over 5 years. European Journal of Gastroenterology & Hepatology 2009; 21(10): 1168 doi: 10.1097/MEG.0b013e32832b125c
|
| 33 |
Maria Teresa Vietri, Gabriele Riegler, Marialaura De Paola, Serena Simeone, Maria Boggia, Alessia Improta, Mariarita Parisi, Anna Maria Molinari, Michele Cioffi. I219V Polymorphism in hMLH1 Gene in Patients Affected with Ulcerative Colitis. Genetic Testing and Molecular Biomarkers 2009; 13(2): 193 doi: 10.1089/gtmb.2008.0088
|
| 34 |
N Nazareth, F Magro, J Silva, M Duro, D Gracio, R Coelho, R Appelberg, G Macedo, A Sarmento. Infliximab therapy increases the frequency of circulating CD16+ monocytes and modifies macrophage cytokine response to bacterial infection. Clinical and Experimental Immunology 2014; 177(3): 703 doi: 10.1111/cei.12375
|
| 35 |
Jørgen Jahnsen, Trond Espen Detlie, Simen Vatn, Petr Ricanek. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Review of Gastroenterology & Hepatology 2015; 9(sup1): 45 doi: 10.1586/17474124.2015.1091308
|
| 36 |
Kunio Asonuma, Keiji Ozeki, Hajime Yamazaki, Shinji Okabayashi, Soh Okano, Ryo Ozaki, Nobuaki Nishimata, Hiroki Kiyohara, Naoki Ichinari, Taku Kobayashi, Masahiro Yamada, Mao Matsubayashi, Yoko Yokoyama, Shoko Arimitsu, Junji Umeno, Yoshinori Munetomo, Akira Andoh, Shinichiro Shinzaki. Immunomodulators after the discontinuation of anti‐tumor necrosis factor‐alpha antibody treatment and relapse in ulcerative colitis: A multicenter cohort study. Journal of Gastroenterology and Hepatology 2024; 39(1): 66 doi: 10.1111/jgh.16376
|
| 37 |
J. LINDSAY, Y. S. PUNEKAR, J. MORRIS, G. CHUNG‐FAYE. Health‐economic analysis: cost‐effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease – modelling outcomes in active luminal and fistulizing disease in adults. Alimentary Pharmacology & Therapeutics 2008; 28(1): 76 doi: 10.1111/j.1365-2036.2008.03709.x
|
| 38 |
Marie Muller, Ferdinando D’Amico, Stefanos Bonovas, Silvio Danese, Laurent Peyrin-Biroulet. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. Journal of Crohn's and Colitis 2021; 15(5): 840 doi: 10.1093/ecco-jcc/jjaa186
|
| 39 |
M. Kraemer, A. Kirschmeier, T. Marth. Perioperative adjuvant therapy with infliximab in complicated anal crohn’s disease. International Journal of Colorectal Disease 2008; 23(10): 965 doi: 10.1007/s00384-008-0500-6
|
| 40 |
Eun Suk Jung, Ko‐woon Choi, Seung Won Kim, Matthias Hübenthal, Sören Mucha, Jihye Park, Zewon Park, David Ellinghaus, Stefan Schreiber, Andre Franke, Woo Yong Oh, Jae Hee Cheon. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases. Journal of Gastroenterology and Hepatology 2019; 34(10): 1727 doi: 10.1111/jgh.14652
|